Literature DB >> 3525676

The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing.

V L Tesh, R L Duncan, D C Morrison.   

Abstract

We have examined the killing of E. coli and kinetics of lipopolysaccharide (LPS) release after the exposure of the bacteria to normal human serum (NHS) and sera deficient in complement components, or with inactivated complement components. LPS of the galactose epimerase-deficient strain E. coli J5 were specifically radiolabeled by growing the bacteria in a medium containing [3H]galactose. Exposure of the washed bacteria to NHS resulted in a significant reduction (greater than 99%) in viability within 15 min and the concomitant release of radiolabeled LPS. However, maximal release of LPS was consistently 30% of the total radiolabel incorporated into the LPS molecules. The amount of tritium-labeled LPS released was shown to be directly proportional to the concentration of bacteria exposed to NHS, suggesting that release of LPS was not limited by the availability of some critical serum component(s). The consumption of complement in NHS by incubation with E. coli was demonstrated by decreased alternative and classical pathway-specific hemolytic activity. The use of Factor D-depleted and VEM-treated human sera demonstrated that, with these bacteria, both the alternative and classical pathways of complement contribute to bacterial killing and release of LPS. It is noteworthy that, in VEM-treated and Factor D-depleted sera, the rate of killing and the kinetics of LPS release were somewhat slower as compared to control serum. Bacterial killing in C7-depleted and C9-deficient human sera was minimal. Neither killing nor LPS release occurred in heat-inactivated (56 degrees C, 30 min) human serum. The amount of [3H]LPS released by C9-deficient serum was qualitatively similar to the amount released by the action of NHS. Tritium-labeled LPS was not released in C7-depleted serum. These data indicate that bacterial killing can be dissociated from LPS release, and suggest that, whereas LPS release may be necessary for the bactericidal effects of serum complement, it is probably not sufficient to effect killing. Furthermore, a significant fraction of LPS can be removed from the outer membrane of the bacteria without an apparent affect on viability.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3525676

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum.

Authors:  J Hellman; P M Loiselle; M M Tehan; J E Allaire; L A Boyle; J T Kurnick; D M Andrews; K Sik Kim; H S Warren
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Peptides related to the carboxyl terminus of human platelet factor IV with antibacterial activity.

Authors:  R P Darveau; J Blake; C L Seachord; W L Cosand; M D Cunningham; L Cassiano-Clough; G Maloney
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin.

Authors:  R T Ellison; T J Giehl; F M LaForce
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

4.  Complement-mediated lipopolysaccharide release and outer membrane damage in Escherichia coli J5: requirement for C9.

Authors:  A M O'Hara; A P Moran; R Würzner; A Orren
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

5.  Separation of sublethal and lethal effects of polymorphonuclear leukocytes on Escherichia coli.

Authors:  B A Mannion; J Weiss; P Elsbach
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

6.  Potent CD14-mediated signalling of human leukocytes by Escherichia coli can be mediated by interaction of whole bacteria and host cells without extensive prior release of endotoxin.

Authors:  S S Katz; K Chen; S Chen; M E Doerfler; P Elsbach; J Weiss
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

Review 7.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

8.  Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance.

Authors:  K C Lamp; M K Vickers
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 9.  Factor H and neisserial pathogenesis.

Authors:  Jo Anne Welsch; Sanjay Ram
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

10.  Reactivity of the human antiendotoxin immunoglobulin M monoclonal antibody HA-1A with lipopolysaccharides from rough and smooth gram-negative organisms.

Authors:  M A Mascelli; B Frederick; T Ely; D S Neblock; D J Shealy; K Y Pak; P E Daddona
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.